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ABSTRACT
Introduction Clinical recommendations for childhood 
asthma are often based on data extrapolated from 
studies conducted in adults, despite significant 
differences in mechanisms and response to treatments. 
The Paediatric Asthma in Real Life (PeARL) Think Tank 
aspires to develop recommendations based on the best 
available evidence from studies in children. An overview 
of systematic reviews (SRs) on paediatric asthma 
maintenance management and an SR of treatments for 
acute asthma attacks in children, requiring an emergency 
presentation with/without hospital admission will be 
conducted.
Methods and analysis Standard methodology 
recommended by Cochrane will be followed. Maintenance 
pharmacotherapy of childhood asthma will be evaluated 
in an overview of SRs published after 2005 and 
including clinical trials or real- life studies. For evaluating 
pharmacotherapy of acute asthma attacks leading to an 
emergency presentation with/without hospital admission, 
we opted to conduct de novo synthesis in the absence of 
adequate up- to- date published SRs. For the SR of acute 
asthma pharmacotherapy, we will consider eligible SRs, 
clinical trials or real- life studies without time restrictions. 
Our evidence updates will be based on broad searches 
of Pubmed/Medline and the Cochrane Library. We will 
use A MeaSurement Tool to Assess systematic Reviews, 
V.2, Cochrane risk of bias 2 and REal Life EVidence 
AssessmeNt Tool to evaluate the methodological quality 
of SRs, controlled clinical trials and real- life studies, 
respectively.
Next, we will further assess interventions for acute severe 
asthma attacks with positive clinical results in meta- 
analyses. We will include both controlled clinical trials 
and observational studies and will assess their quality 
Strengths and limitations of this study
 ► Broad evidence syntheses on the management of 
childhood asthma, with a focus on the differential 
treatment response according to age and disease 
phenotypes could reveal clinically exploitable infor-
mation, that will be used in the development of clin-
ical and research recommendations by Paediatric 
Asthma in Real Life.
 ► A rigorous methodology that includes thorough eval-
uation of the literature, appropriate evaluation of the 
methodological quality of individual studies and—
when appropriate—of the body of evidence, and 
presentation of overall effect estimates.
 ► A prospectively published protocol increases the 
transparency and allowed for peer- review of the 
methodology used.
 ► A potential limitation of the overview of systematic 
reviews (SRs) is that the feasibility of conducting the 
planned subgroup analyses will depend on whether 
relevant data have been captured in existing SRs.
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using the previously mentioned tools. We will employ random effect 
models for conducting meta- analyses, and Grading of Recommendations 
Assessment, Development and Evaluation methodology to assess certainty 
in the body of evidence.
Ethics and dissemination Ethics approval is not required for SRs. Our 
findings will be published in peer reviewed journals and will inform clinical 
recommendations being developed by the PeARL Think Tank.
PROSPERO registration numbers CRD42020132990, 
CRD42020171624.
INTRODUCTION
Having a global prevalence that is anticipated to exceed 
400 million children by the year 2025, childhood asthma 
represents a huge health and socioeconomic burden 
to patients, their families and the society.1–3 Despite its 
diverging mechanisms, triggers, outcomes and response 
to treatment, childhood asthma is often still approached 
as an extension of adult asthma.4 It is underaddressed 
in clinical guidelines, likely due to unclear diagnosis, 
limited availability of safety, efficacy and effectiveness data 
in this population. Clinical recommendations are to a 
large extent informed by data extrapolated from clinical 
studies conducted in adults. 2–5
Numerous challenges complicate conducting interven-
tional research studies in children with asthma. Besides 
the lack of consensus on its definition and diagnostic 
criteria, childhood asthma is highly heterogeneous and 
our understanding of different paediatric asthma pheno-
types is still limited or contradictory.6 This is further 
emphasised by significant variability in disease progres-
sion, outcomes and treatment response in children with 
different phenotypes or ages5,7 potentially complicating 
interpretation of trials’ findings. In addition, there are 
regulatory and ethical constraints in conducting inter-
ventional research in children.8 9 However, this results 
in the administration of treatments that have not been 
adequately evaluated in relevant (paediatric) popula-
tions, that is, evidently suboptimal.
Paediatric Asthma in Real Life (PeARL), an interna-
tional Think Tank focusing on paediatric asthma, was 
initiated in the context of the respiratory effectiveness 
group, to address this evidence deficit. In a recent inter-
national, multistakeholder survey, we have identified 
and prioritised unmet needs on paediatric asthma.10 A 
need for systematic evidence updates focusing on the 
management of asthma in different age groups emerged. 
Herein, we present the protocol for a series of systematic 
evidence updates aiming to summarise direct evidence 
from clinical studies in children with asthma, evaluating 
the safety and clinical effectiveness of pharmacological 
interventions for maintenance management and for 
the treatment of acute severe asthma attacks, defined as 
those leading to an emergency presentation with/without 
hospital admission, in different age groups. Our work will 
be used to inform clinical recommendations being devel-
oped by the PeARL Think Tank. Therefore, we need solid 
evidence on the efficacy on safety of various interventions. 
It is considered crucial to incorporate evidence derived 
from real- life observational studies, which may carry a 
lower strength of evidence than randomised controlled 
trials (RCTs), but are available in higher abundance and 
provide a better representation of clinical practice in real 
life, where for example, treatment compliance or inhaler 
technique may be problematic.
METHODS AND ANALYSIS
We will conduct two systematic evidence updates, based 
on protocols prospectively registered in the PROSPERO 
register (CRD42020132990,11 CRD4202017162412). The 
first will evaluate the safety and clinical effectiveness of 
pharmacological maintenance treatments for childhood 
asthma, while the other will focus on the pharmaco-
therapy of acute severe asthma attacks, defined as those 
requiring a hospital admission or emergency presenta-
tion. We will use standard methodology recommended 
by the Cochrane Collaboration13 and will follow the 
Preferred Reported Items for Systematic Reviews and 
Meta- Analyses statement.14
Preliminary searches revealed several RCTs evalu-
ating maintenance pharmacotherapy of childhood 
asthma, which have already been summarised in high- 
quality systematic reviews (SRs), some conducted by the 
Cochrane Collaboration. We identified >40 up- to- date 
SRs evaluating inhaled corticosteroids (ICS), long- acting 
beta-2 agonists (LABA), long- acting muscarinic antago-
nists (LAMA), leukotriene receptor antagonists (LTRA) 
or biologic therapies, as first line or add- on treatment 
for asthma in children. As a result, we opted to produce 
an overview of existing SRs of clinical trials and real- life 
studies.15.
We found less up- to- date SRs on the management of 
acute severe asthma attacks in children, mainly focusing 
on short- acting beta-2 agonists (SABA), short acting 
muscarinic antagonists, oral corticosteroids, aminophyl-
line and magnesium that were recently summarised in a 
Cochrane Overview of SRs.16 However, when evaluating 
the literature, we identified several other pharmacolog-
ical interventions that are tested in small trials or real- life 
studies, and while they may show promising early results, 
they have not been assessed further or introduced in 
clinical practice guidelines.17–23 For this reason, we will 
conduct de novo synthesis of comparative clinical studies 
of any design aiming to identify any pharmacological 
intervention that has been tested for acute severe asthma 
attacks, followed by focused meta- analyses of promising 
interventions not covered by existing high- quality SRs or 
clinical practice guidelines.
Overview of SRs evaluating maintenance pharmacotherapy for 
paediatric asthma
Eligibility criteria
Eligible studies will comprise SRs and meta- analyses of 
controlled clinical trials or of real- life studies evaluating 
maintenance treatments that are broadly used in clin-
ical practice for asthma or recurrent wheeze in children 
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and adolescents, aged up to 18 years. More specifically, 
we will include SRs comparing any combination of ICS, 
LABA, LAMA, LTRA, biological therapies (namely omal-
izumab, mepolizumab, reslizumab, benralizumab or 
dupilumab), or placebo as monotherapy or add- on main-
tenance therapy for paediatric asthma. We will accept SRs 
and meta- analyses evaluating any molecule of the above- 
mentioned categories, administered at any dose and for 
a duration of at least 6 weeks. SRs comparing asthma 
maintenance treatment both in children and adults will 
be included provided that paediatric data are presented 
separately. We will only include SRs published between 
2005 and December 2020 and reported in the English 
language. Older SRs are probably outdated and will only 
be considered in the absence of high- quality, newer SRs.
Outcome measures
The primary outcomes of this overview will be the number 
of acute attacks requiring the administration of oral corti-
costeroids or an emergency visit, and the number of acute 
attacks requiring hospitalisation. Secondary outcomes will 
include lung function measures, acute attacks irrespec-
tive of the severity, symptom scores (including symptom 
free and rescue medication free days), asthma control, 
asthma- specific quality of life scores, use of rescue medi-
cations, withdrawal rates (overall, due to lack of efficacy 
or adverse events), adverse events and serious adverse 
events.
Search strategy and study selection
The electronic databases of Medline/PubMed and 
Cochrane Library will be systematically searched, using 
appropriate controlled vocabulary and free search 
terms to identify relevant SRs (terms describing: child-
hood asthma, LABA, LAMA, LTRA, ICS, biologics, SRs, 
detailed search strategy is available in online supple-
mental appendix). Databases will be searched from 2006 
onwards. Titles and abstracts of all identified manuscripts, 
and the full texts of potentially relevant manuscripts, 
will be screened by two investigators independently. We 
will report the reasons of exclusion of studies that will 
be excluded after full- text review. Disagreement will be 
resolved through discussion or adjudication by a third 
investigator, when necessary.
Data abstraction
For each of the included SRs, one investigator will extract 
the full reference and study identifiers, references of the 
included trials evaluating paediatric populations, eligi-
bility criteria, predefined outcomes, number and base-
line characteristics of the participants and details on the 
outcomes of interest. A second investigator will cross- 
check for validity.
Risk of bias assessment
A MeaSurement Tool to Assess systematic Reviews, V.2 
(AMSTAR 2) tool will be used to evaluate the methodolog-
ical quality of all included SRs.24 25 The AMSTAR 2 tool 
evaluates 16 domains, focusing on the methodological 
design, interpretation and potential risk of bias involved 
in the conduct of a SR. It is considered by the AMSTAR 2 
team that seven domains could critically affect the validity 
of the review, while the remaining domains describe non- 
critical weaknesses. Critical flaws for an SR include (1) 
lack of prospective protocol registration, (2) inadequate 
literature searches, (3) lack of justification of excluding 
individual studies, (4) of risk of bias evaluation or (5) of 
risk of bias consideration in interpreting the results, (6) 
of assessment of presence and likely impact of publica-
tion bias and (7) inadequate methodology for conducting 
meta- analysis. We will consider the results of an SR of high 
quality, if there is only one or none non- critical weakness, 
and of moderate quality, if there are more than one non- 
critical weaknesses. If there are one or more critical weak-
nesses, then we will consider the confidence low or very 
low, respectively. Two of the SRs will evaluate the risk of 
bias independently and disagreement will be resolved 
through discussion, or adjudication by a third reviewer.
Qualitative synthesis
We will summarise descriptively or in a tabulated format 
the characteristics of the included SRs and outcomes of 
interest. When several SRs evaluate the same intervention, 
we will compare their eligibility criteria, included studies 
and methodological quality as evaluated by the AMSTAR-2 
tool, as well as the pertinent subgroup analyses that are 
presented. We will present in detail the results of the SR 
that is most recent, more complete and of high method-
ological quality. If no single SR fulfil these criteria, we will 
present in detail more than one SRs. From the remaining 
SRs, we will present pertinent additional information that 
may include, such as details about additional outcomes, 
or additional subgroups.
We will specifically report on the differential effective-
ness of the interventions across different maintenance 
treatment steps (severity), age groups or paediatric 
asthma phenotypes.
SR of clinical studies evaluating the management of acute 
severe asthma attacks
Over the past decades, several interventions have been 
tested for the management of acute severe asthma attacks, 
such as ketamine or macrolide antibiotics.17–23 Despite 
promising early findings, some of these interventions 
were not further tested in robust, prospective controlled 
clinical trials. This may partially be due to challenges in 
conducting experimental clinical studies in children, 
as previously discussed, particularly during acute, life- 
threatening conditions.
To identify all evaluated treatments, a two- stage 
approach will be followed. First, a broad search strategy 
will be used to identify all pharmacological interventions 
that have been tested as potential treatments for acute 
severe asthma attacks. Next, medications that showed 
positive clinical results, but are not yet thoroughly eval-
uated in clinical studies and meta- analyses and are 
therefore not recommended by international asthma 
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guidelines (such as the National Institute for Health and 
Care Excellence asthma guidelines, the British Thoracic 
Society and Scottish Intercollegiate Guidelines Network 
asthma guidelines, the National Asthma Education and 
Prevention Programme or the Global Strategy for Asthma 
Management and Prevention document), will be selected 
and further evaluated in individual meta- analyses. The 
aim will be to identify novel interventions that could 
be recommended for use in clinical practice, or might 
require further evaluation in clinical research studies, to 
confirm their safety and effectiveness profiles.
BROAD SR
Medline/PubMed and the Cochrane Library will be 
searched, using a broad search strategy, aimed to identify 
any clinical research studies evaluating the management 
of acute severe asthma attacks (detailed search strategy is 
available in online supplemental appendix).
Any study evaluating pharmacological treatments 
for acute severe asthma attacks in children and adoles-
cents (<18 years of age) will be included. Any compara-
tive clinical research study, including experimental and 
observational studies, as well as SRs of such studies will 
be considered eligible for inclusion. We will only include 
studies published until May 2021 and reported in the 
English language, without time restrictions.
Eligible studies will be grouped according to the drug 
category they evaluate and will be presented narratively. 
Study design, characteristics and outcomes of interest 
will be reported descriptively or in a tabulated format. 
Outcomes of interest are the same for this broad SR and 
individual medication meta- analyses and are detailed in 
the next section.
INDIVIDUAL MEDICATION META-ANALYSES
These meta- analyses will further evaluate the safety and 
clinical effectiveness of individual medications that were 
assessed by the initial broad SR and were found to be of 
potential clinical value for the treatment of acute severe 
asthma attacks. In contrast to most preceding SRs and 
meta- analyses, we will include data from observational 
comparative effectiveness (real- life) studies, as well as 
controlled clinical trials.
Eligibility criteria
For each meta- analysis, eligible studies will comprise 
controlled clinical trials and observational comparative 
effectiveness studies comparing the index medication 
with placebo, no treatment or any active control, as an 
add- on treatment for acute severe asthma attacks. Index 
medication will be defined based on the pharmacological 
action, meaning that molecules targeting the same phar-
macological target (eg, salbutamol and terbutaline, both 
being SABA) will be grouped. Only studies evaluating 
the management of acute severe asthma attacks, defined 
as those requiring a hospital admission or emergency 
presentation, in children and adolescents, aged between 
1 and 18 years of age will be included. Studies evaluating 
both children and adults will be included, provided that 
paediatric data are reported separately or that we will be 
able to access these data after requesting them from the 
investigators. We will only include observational studies 
that meet the primary criteria of the REal Life EVidence 
AssessmeNt Tool (RELEVANT) tool (see risk of bias). 
We will include studies published until May 2021 and 
reported in the English language.
Outcome measures
The primary outcome measures will be (1) treatment 
success or treatment failure rate evaluated at any time 
point, within 2 weeks from presentation, (2) serious 
adverse events and (3) need for asthma related hospital-
isation evaluated at any tim epoint within 2 weeks from 
presentation. Treatment success will be defined as a 
complete resolution of the symptoms, or an improvement 
in the clinical signs, symptoms and/or laboratory find-
ings that fulfils specific criteria or thresholds prespecified 
by the study team. Treatment failure will be defined as 
a significant deterioration of the patients’ clinical condi-
tions that fulfils specific criteria prespecified by the study 
team. For example, treatment failure may be defined as the 
need for paediatric intensive care unit admission, ventila-
tion or death. The definitions of treatment success and 
treatment failure vary significantly across clinical studies 
evaluating the management of acute asthma in children; 
for this reason, meta- analyses will only be conducted in 
cases they are considered meaningful by the investiga-
tors. Need for asthma- related hospitalisation will not be 
relevant for studies only evaluating hospitalised partici-
pants. Secondary outcomes will include (1) mortality, (2) 
duration of asthma- related hospitalisation, (3) need for 
intensive care unit admission, (4) duration of intensive 
care unit stay, (5) re- exacerbation rate, (6) rehospital-
isation rate and (7) adverse events. All outcomes will be 
evaluated at a maximum follow- up of 6 months, as longer- 
term outcomes are less likely to be directly linked with the 
index acute event.
Search strategy and study selection
Using appropriate controlled vocabulary and free search 
terms, we will systematically search Medline/PubMed, 
EMBASE and the Cochrane Library to identify controlled 
clinical trials and observational comparative effective-
ness studies evaluating the safety, efficacy and/or clin-
ical effectiveness of the selected medication (sample 
search strategies are available in the online appendix). 
We will also search the WHO International Clinical Trials 
Registry Platform search portal, the abstract proceed-
ings of the European Respiratory Society, the American 
Thoracic Society, the Asian Pacific Society of Respirology, 
the European Academy of Allergy and Clinical Immu-
nology, the American Academy of Allergy, Asthma and 
Immunology, and the World Allergy Organization, as well 
as the reference lists of all included studies. All sources 
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will be searched from inception, without language limita-
tions. We will follow standard methodology for screening 
titles, abstracts and the full text of all identified studies, as 
described previously.
Data abstraction
The full study reference, study identifiers, details on the 
study design, eligibility criteria, predefined outcomes and 
potential confounding factors that were considered by 
the investigators, number and baseline characteristics of 
participants will be extracted by one investigator and will 
be cross- checked for validity by a second extractor. Details 
on the outcomes of interest from all included studies will 
be extracted by two investigators independently. Conflicts 
will be resolved through discussion and when needed 
adjudication by a third investigator.
Risk of bias of individual studies
We will use the second version of the Cochrane risk of 
bias (RoB2) tool for assessing risk of bias in the included 
RCTs26 and the RELEVANT for assessing the risk of bias 
of observational studies.27 Risk of bias of each included 
study will be evaluated by two investigators independently.
The RoB2 tool evaluates the following domains for 
potential risk of bias: (1) bias arising from the randomi-
sation process, (2) bias due to deviations from intended 
interventions, (3) bias due to missing outcome data, (4) 
bias in measurement of the outcome, (5) bias in selection 
of reported results and (6) any other potential source of 
bias. High risk of bias in any of these domains will result in 
an overall judgement of high risk of bias. In the absence 
of high- risk domains, unclear risk in any domain will lead 
to an overall judgement of unclear risk. All remaining 
trials will be considered to be of low risk of bias.
RELEVANT evaluates the quality of observational 
comparative effectiveness research studies across seven 
domains, which include background, design, measures, 
analysis, results, discussion/interpretation and conflicts 
of interest. Each domain includes primary and secondary 
items. It is suggested that studies not meeting the primary 
items of RELEVANT are of very low methodological quality 
(have ‘fatal flaws’) and should not be used to inform clin-
ical recommendations. Therefore, we will exclude studies 
not meeting these criteria. We will consider of low risk of 
bias all studies meeting the secondary criteria of RELE-
VANT as well, and of high risk of bias studies that do not 
meet any of the secondary criteria.
For every comparison, we will use funnel plots, Egger’s 
regression and Begg’s rank tests to evaluate publication 
bias, if we are able to pool more than 10 studies.
Data synthesis
Data from controlled clinical trials or observational studies 
will be analysed separately. In addition, studies evaluating 
different comparators, will be analysed separately. If 
different doses of the index medication or comparator 
are evaluated across the included studies, we will consider 
grouping studies using similar doses, providing that their 
results are not significantly dissimilar.
For every analysis, I2 statistic will be used to assess statis-
tical heterogeneity. Substantial heterogeneity (I2 >50%) 
will be explored using prespecified subgroup analyses 
(details in the next section). We will not perform meta- 
analyses in cases of considerable unresolved heteroge-
neity (I2 >75%).
When it is considered meaningful, meta- analyses will be 
performed using the random- effects model, because we 
anticipate significant heterogeneity in our data. Results 
will be presented in the form of relative risk (95% CI) 
for dichotomous data, mean difference (95% CI) for 
continuous data and (HR, 95% CI) for time to event data. 
Meta- analyses will be performed using Review Manager 
V.5 (RevMan, http:// community. cochrane. org/ tools/ 
review- production- tools/ revman- 5) and R statistics 
V.3.4.3 or newer (R Foundation for Statistical Computing, 
Vienna, Austria).
For dichotomous outcomes, the unit of analysis will 
preferably be participants, rather than events (ie, number 
of participants admitted to the intensive care unit, rather 
than number of admissions per participants).
Sensitivity and subgroup analyses
In sensitivity analyses for all comparisons, we will (1) use 
fixed effects models, (2) only include studies with low risk 
of bias, (3) exclude studies reporting limited adherence 
to the study drugs (<80%) and (4) evaluate separately 
studies assessing different doses of the index medication, 
which we may pool in the main analysis.
Subgroup analyses according to participants’ age, 
asthma phenotypes or, possibly, acute attack phenotypes 
will also by conducted, depending on data availability. In 
an additional subgroup analysis, we will evaluate sepa-
rately trials utilising exploratory versus pragmatic study 
designs.
Certainty of the body of evidence
Certainty of the body of evidence, for every comparison 
will be evaluated using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
methodology.28 GRADE assesses the certainty in a body of 
evidence as high, moderate, low or very low after consid-
ering the methodological quality of the included studies, 
imprecision, inconsistency, indirectness, publication bias, 
the magnitude of effect, dose response and confounders 
likely to minimise the effect. All decisions to upgrade or 
downgrade the quality of evidence will be transparent 
and justified in evidence profile and summary of evidence 
tables, in accordance with GRADE guidance. GRADEPro 
Software (2014; www. gradepro. org) will be used for the 
development of these tables.
We will use GRADE methodology to assess the risk of 
bias associated with missing participant outcome data 
across the body of the available evidence.29 GRADE 
suggests repeating the primary meta- analysis, imputing 
the most extreme assumptions about the values of the 
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missing data, that the investigators consider plausible. 
Only if the analyses prove robust to this imputation, 
the risk of bias due to missing participant outcome data 
should be deemed low.
The impact that the risk of bias of individual studies 
and the confidence in the body of the evidence has on 
the results will be presented.
ETHICS AND DISSEMINATION
Ethical approval is not required for these SRs, since no 
primary data will be collected.
The findings of these evidence updates will be 
presented in national and international scientific confer-
ences. They will also be submitted for publication in 
high- impact peer review journals. Plain English summa-
ries of the final reports will be developed and shared with 
relevant patient organisations. Moreover, our results will 
be used to inform clinical recommendations that will be 
developed by the PeARL Think Tank. We anticipate that 
the overview of SRs will be completed by the end of 2021 
and the remaining SRs by June 2022.
PATIENT AND PUBLIC INVOLVEMENT
The planned SRs were prioritised through a global, 
multi- stakeholder survey evaluating research priorities 
in childhood asthma, conducted by the PeARL Think 
Tank.10 Among other stakeholders, this survey included 
responses from patients, patient caregivers and patient 
organisations. Moreover, two patient representatives 
(GDC and TAW) have joined the research group and 
provided input in this study protocol and they will also 
provide input throughout the study process.
DISCUSSION
We report on the methodology of a series of planned 
systematic evidence updates, aiming to evaluate main-
tenance management of childhood asthma, and the 
treatment of acute severe asthma attacks. Their design 
is informed by preliminary searches and the anticipated 
data availability. These SRs will be conducted by the 
PeARL group and will be used to inform clinical recom-
mendations and future research needs. The need for 
high- quality evidence updates and clinical practice guide-
lines to improve the management of asthma in children 
is more urgent now, given the pressure that the unfolding 
COVID-19 pandemic pose on the healthcare systems, 
forcing us to reconsider our daily clinical practice.30 31
Major strengths of our evidence update series are the 
inclusion of a wide evidence base, including data from 
RCTs and real- life comparative studies, the prospective 
design and strong methodology. The methodological 
quality of all available studies will be scrutinised and will 
aid the interpretation of our findings. Moreover, we will 
attempt to evaluate differential therapeutic response of 
different asthma phenotypes and age groups. We believe 
this analysis will be revealing, if adequate data is available, 
but may nevertheless reveal important gaps.
Guided by the available evidence, we will follow different 
strategies for the evidence updates on maintenance treat-
ment of paediatric asthma and on management of acute 
severe asthma attacks. In view of the availability of ample 
published, up- to- date SRs on maintenance pharmacotherapy 
of childhood asthma, we chose to conduct an overview of 
SRs. We decided to focus on the most frequently used and 
thoroughly evaluated drug classes (ICS, LABA, LAMA, 
LTRA and biological therapies) and we expect to identify 
good quality data, which would inform clinical practice and 
research needs. Other, less frequently or experimentally 
used treatments will need to be evaluated in future studies. 
A potential limitation of this approach is that we might not 
be able to capture adequate data regarding the differential 
effectiveness of interventions across different severity groups, 
age groups or paediatric asthma phenotypes, if these have not 
been captured in existing SRs. Moreover, existing SRs may 
not capture some of the most recent studies, that may have 
been published after the SRs, although preliminary searches 
have revealed several very recently update meta- analyses.
The second SR, focusing on the management of acute 
attacks, will first evaluate a multitude of established and 
experimental treatments. With regard to the latter, this 
SR will reveal treatments that have been tested, appeared 
safe and efficacious and it may be worth to be further 
evaluated, but will also report on interventions that 
were tested, but did not appear efficacious, and there-
fore, further evaluation may not be beneficial. This wide 
approach would aid the prioritisation of interventions to 
be further validated in future clinical research studies.
Next, meta- analyses of individual pharmacological 
interventions will be conducted to further assess the safety 
and clinical effectiveness of treatments for acute severe 
asthma attacks that will appear efficacious in our broad 
SR. In contrast to most previous meta- analyses, that may 
have been conducted, we will include both controlled 
clinical trials and observational comparative effective-
ness studies. Due to limitations that have already been 
discussed, few controlled clinical trials are conducted in 
children. This leads several Cochrane SRs to report low 
or very low confidence in the body of evidence, due to 
the lack of data.32–35 We believe that by incorporating data 
from observational studies we may be able to conclude 
more robust results. While observational studies are at a 
higher risk of bias, we will carefully evaluate this risk using 
the newly developed, thorough RELEVANT tool and we 
will discuss potential implications on our findings. The 
GRADE working groups provides transparent guidance 
for assessing the certainty in a body of evidence including 
data from different study designs (controlled clinical 
trials or observational studies); this guidance will be used 
for interpreting the findings of our meta- analyes.
Overall, we aim to develop evidence updates on the mainte-
nance treatment of asthma and management of acute severe 
asthma attacks that will cover all available evidence, carefully 
considering methodological limitations. These will be used 
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by the PeARL Think Tank for the development of clinical 
recommendations and to guide future clinical research.
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